Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ferric · 6 trials · 11 indications
Efficacy analyses were performed for the Intention-to-treat (ITT) population, the population consisted of all subjects who were randomized, had a baseline laboratory value, took at least 1 dose of study drug, and had at least 1 post-baseline laboratory assessment during the randomized period.
Safety was assessed by recording and monitoring adverse events (AEs), serious adverse events (SAEs), and sequential laboratory data. Rates of AEs were summarized by system organ class, preferred term, severity, and suspected relationship to KRX-0502 (ferric citrate).
Mean change from baseline was calculated separately for each treatment arm (LOCF)
The difference in TSAT between the value at the end of treatment (week 12) minus the baseline measurement.
The difference in serum phosphorus between the value at the end of treatment (week 12) minus the baseline measurement.
| Arm | Type | Description |
|---|---|---|
| Ferric Citrate | ACTIVE_COMPARATOR | Ferric citrate (FC) will be supplied as tablets containing 210mg of ferric iron (as 1g ferric citrate) to those subjects randomized to FC. These participants will be initiated on study drug with a fixed dose of FC beginning with 2 tablet per meal. |
| Standard of Care (SOC) | NO_INTERVENTION | Participants may receive open-label, non-FC phosphate binders at the discretion of their treating physician. During the Dialysis Period, dose of phosphate binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study. |
| KRX-0502 (ferric citrate) | EXPERIMENTAL | 1 g of KRX-0502 (ferric citrate) containing approximately 210 mg of ferric iron |
| Placebo | PLACEBO_COMPARATOR | Matching Placebo |
| 1 g/day | EXPERIMENTAL | 1 g/day KRX-0502 (ferric citrate) |
| 6 g/day | EXPERIMENTAL | 6 g/day KRX-0502 (ferric citrate) |
| 8 g/day | EXPERIMENTAL | 8 g/day KRX-0502 (ferric citrate) |
| Name | Type | Description |
|---|---|---|
| Ferric Citrate | DRUG | Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis |
| Placebo | DRUG | Matching placebo |
Inclusion Criteria: 1. Age \>18 years at screening visit 2. Serum phosphate \> or equal to 3.0 mg/dL obtained at screening 3. CKD with eGFR \< or equal to 20 mL/min obtained at screening\* 4. Hemoglobin (Hgb) \>8.0 g/dL obtained at screening 5. TSAT \<55% obtained at screening 6. Females of child b...
Top 20 of 25 competitors
Ferric is an investigational small molecule being developed for End Stage Renal Disease, Chronic Kidney Disease, Hyperphosphatemia, Anemia of Chronic Kidney Disease, and Iron Deficiency. It is being studied in patients with kidney disease to manage serum phosphorus and iron deficiency.
Ferric is being developed by Akebia Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker AKBA. The company is conducting clinical trials to evaluate Ferric in patients with kidney disease and related conditions.
Ferric is in Phase 3 clinical development. It has completed multiple trials, including Phase 2 and Phase 3 studies, but it remains investigational and has not been approved by regulatory authorities. Its development is ongoing.
Ferric has been studied in several completed trials, including NCT01554982, a long-term safety extension in End Stage Renal Disease patients on dialysis, and NCT01736397, a Phase 2 study in anemic Chronic Kidney Disease patients not on dialysis.
Yes, Ferric is also known as KRX-0502. A Phase 3 trial, NCT02268994, evaluated KRX-0502 (Ferric Citrate) for the treatment of Iron Deficiency Anemia in adult subjects with non-dialysis dependent Chronic Kidney Disease.